How should a patient with diffuse multinodular goitre and an American College of Radiology Thyroid Imaging Reporting and Data System (ACR TIRADS) 3 (probably benign) thyroid ultrasound be initially managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Diffuse Multinodular Goiter with TIRADS 3 Nodules

For a patient with diffuse multinodular goiter containing TIRADS 3 (probably benign) nodules, measure serum TSH first, then perform ultrasound-guided fine-needle aspiration (FNA) only on nodules ≥2.5 cm or those with additional high-risk clinical features, while observing smaller nodules with annual surveillance ultrasound. 1, 2

Initial Diagnostic Pathway

Measure TSH before any further decisions, as this determines the entire management algorithm and urgency of intervention. 1 The presence of thyrotoxicosis versus euthyroid status fundamentally changes whether you proceed with radionuclide scanning or move directly to nodule characterization. 3

Key Clinical Context to Document

  • History of head and neck irradiation increases malignancy risk approximately 7-fold and lowers the FNA threshold even for TIRADS 3 nodules 1, 4
  • Family history of thyroid cancer, particularly medullary carcinoma or familial syndromes 1, 4
  • Compressive symptoms including dysphagia, dyspnea, choking sensation, or voice changes 2, 5
  • Rapid nodule growth (≥3 mm increase in any dimension) is one of the strongest predictors of malignancy 4

Management Algorithm Based on TSH Results

If TSH is Suppressed (Toxic Multinodular Goiter)

Proceed to radionuclide uptake and scan to identify hyperfunctioning versus isofunctioning/hypofunctioning nodules. 3 Compare the scan to ultrasound findings to target hypofunctioning or isofunctioning nodules for FNA, as these carry higher malignancy risk. 3 Treatment options include radioactive iodine or surgery, with surgery providing more rapid resolution for large goiters with autonomously functioning nodules. 6

If TSH is Normal or Elevated (Nontoxic Multinodular Goiter)

Do not order radionuclide scanning in euthyroid patients, as it has low positive predictive value for malignancy and does not add value for risk assessment. 1, 4 Ultrasound features should guide all management decisions. 4

FNA Decision Algorithm for TIRADS 3 Nodules

TIRADS 3 nodules carry a baseline malignancy risk of approximately 5-13%. 7, 8 The ACR guidelines recommend different size thresholds based on TIRADS category:

Proceed with FNA if:

  • Nodule ≥2.5 cm (standard threshold for TIRADS 3) 2, 8
  • Any size nodule with ≥2 additional suspicious features on ultrasound: marked hypoechogenicity, microcalcifications, irregular margins, absence of peripheral halo, or central hypervascularity 2, 4
  • Nodule ≥1 cm with high-risk clinical factors: history of radiation, family history of thyroid cancer, age <15 years, suspicious cervical lymphadenopathy 1, 4
  • Compressive symptoms clearly attributable to specific nodules 2, 5
  • Documented growth ≥3 mm in any dimension during surveillance 4

Observation is appropriate for:

  • TIRADS 3 nodules <2.5 cm without high-risk clinical features or additional suspicious ultrasound characteristics 2, 8
  • Asymptomatic patients with stable nodule size and normal TSH 6, 5

Surveillance Protocol for Observed Nodules

Perform repeat ultrasound at 12-24 months to assess for interval growth or development of suspicious features. 2, 4 Annual clinical evaluation with TSH measurement and thyroid palpation is sufficient for stable nodules. 6, 5

Do not use CT or MRI for routine surveillance, as ultrasound provides superior resolution for nodule characterization. 4 Reserve CT for evaluating substernal extension or tracheal compression when surgery is being considered. 2

Management Based on FNA Results

Bethesda II (Benign)

Continue surveillance with repeat ultrasound at 12-24 months, as malignancy risk is only 1-3%. 2, 4 However, a reassuring FNA should not override worrisome clinical findings, as false-negative results occur in 11-33% of cases. 4

Bethesda III/IV (Indeterminate)

Consider molecular testing for BRAF, RAS, RET/PTC, and PAX8/PPARγ mutations to refine malignancy risk, as 97% of mutation-positive nodules are malignant. 2, 4 If molecular testing is unavailable or indeterminate, surgery is generally recommended for definitive diagnosis. 2, 5

Bethesda V/VI (Suspicious or Malignant)

Refer immediately for total or near-total thyroidectomy with pre-operative assessment of cervical lymph node compartments. 2, 4

Critical Pitfalls to Avoid

  • Do not skip ultrasound evaluation even if planning specialist referral, as it provides essential information guiding urgency and type of intervention 1
  • Do not proceed directly to radionuclide scanning in euthyroid patients with multinodular goiter 1
  • Do not rely on thyroid function tests (TSH, T3, T4) for malignancy assessment, as most thyroid cancers present with normal thyroid function 4
  • Do not use levothyroxine suppression therapy in patients with suppressed TSH levels, as this risks toxic symptoms without proven benefit for nodule size reduction 6
  • Do not perform FNA on all nodules in a multinodular goiter—select the largest nodule, those with suspicious features, or hypofunctioning nodules on scan 3, 2

When to Refer for Surgery

Immediate surgical referral is indicated for:

  • Malignant or suspicious cytology (Bethesda V/VI) 2, 4
  • Large goiters with compressive symptoms (dysphagia, dyspnea, airway obstruction) 2, 5
  • Substernal extension with tracheal compression 2
  • Toxic multinodular goiter in patients preferring definitive treatment over radioiodine 6, 5

Endocrinology consultation is recommended for managing indeterminate cytology, applying TIRADS criteria for nodule selection, and coordinating surveillance protocols. 1

References

Guideline

Evaluation and Management of Growing Painful Thyroid Nodules in Goiter

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Thyroid Ultrasound vs CT for Detecting Thyroid Nodules

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

acr appropriateness criteria<sup>®</sup> thyroid disease.

Journal of the American College of Radiology, 2019

Guideline

Ultrasound-Guided FNA Biopsy for Thyroid Nodules

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Approach to the patient with nontoxic multinodular goiter.

The Journal of clinical endocrinology and metabolism, 2011

Research

Evaluation and management of multinodular goiter.

Otolaryngologic clinics of North America, 1996

Research

Evaluation of Thyroid Nodule: Thyroid Imaging Reporting and Data System (TIRADS) and Clinicopathological Correlation.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2022

Related Questions

What is the management approach for a patient with a benign colloid nodule and toxic multinodular (c) goitre?
In a 76‑year‑old female with a non‑toxic multinodular goitre on carbimazole 5 mg twice daily, suppressed thyroid‑stimulating hormone, low‑normal triiodothyronine, elevated thyroxine, and HbA1c 6.01 % undergoing pre‑operative assessment for orthopedic hip surgery, what endocrine review and peri‑operative management should be documented?
In a patient with a large asymmetrically enlarged right thyroid lobe showing multinodular goiter with substernal/mediastinal extension, mild leftward tracheal shift, an aberrant retro‑esophageal right subclavian artery, and no significant airway narrowing or pathologic lymphadenopathy, what are the appropriate next diagnostic and management steps?
According to the American Thyroid Association guidelines, what postoperative management and surveillance are recommended for a patient with multiple non‑toxic goiters who has undergone total thyroidectomy?
How should brittle hypothyroidism be managed in a patient with multinodular goitre?
What drugs should not be co‑administered with NyQuil (acetaminophen, dextromethorphan, doxylamine, phenylephrine)?
In an adult being evaluated for possible hypercortisolism, how should I obtain and interpret a midnight cortisol level?
In a patient with IBS‑C or chronic idiopathic constipation who has taken linaclotide (Linzess) at the appropriate dose for ≥4 weeks and still has severe constipation, what is the next step in management?
What is the typical postoperative recovery period and activity/diet restrictions for an adult undergoing laparoscopic hiatal hernia repair?
How do the mechanisms of action of allopurinol and rasburicase differ?
Does tirzepatide increase serum creatinine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.